Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
According to the Padova international classification, 52 gastric noninvasive neoplasias (NIN) were classified as follows: 20 low-grade NIN (L-NIN); 9 high-grade NIN including suspicion for carcinoma without invasion (H-NIN); and 23 high-grade NIN including carcinoma without invasion (Ca-NIN). The molecular and cellular phenotypic profiles were investigated and compared. The APC gene was mutated in seven (35%) L-NIN, two (22%) H-NIN, and two (9%) Ca-NIN tumors; APC mutations were significantly more frequent in L-NIN compared with Ca-NIN tumors (p < 0.05). Mutations of the
p53
gene were found in five (22%) Ca-NIN tumors but were not observed in L-NIN or H-NIN tumors (p < 0.05). Loss of heterozygosity involving at least one chromosomal locus was detected in 14 (61%) Ca-NIN tumors but was not detected in L-NIN or H-NIN tumors. High-frequency microsatellite instability (MSI-H) was detected in one (5%) L-NIN tumor and in six (26%) Ca-NIN tumors. The frequencies of loss of heterozygosity and MSI-H were significantly higher in Ca-NIN than in L-NIN or H-NIN tumors (p < 0.05). Nuclear accumulation of
p53 protein
was detected in no L-NIN tumors, 1 (11%) H-NIN tumor, and 10 (44%) Ca-NIN tumors (p < 0.01). All tumors with loss of
hMLH1
expression exhibited MSI-H (p < 0.01). Cellular phenotypic analysis revealed that seven (35%) L-NIN tumors and one (4%) Ca-NIN tumor had complete-type intestinal metaplastic phenotype and that one (5%) L-NIN tumor and one (4%) Ca-NIN tumor had a gastric foveolar epithelial phenotype, whereas the remaining tumors exhibited an ordinary phenotype. Thus, the complete-type intestinal metaplastic phenotype was more characteristic of L-NIN tumors than of H-NIN or Ca-NIN tumors (p < 0.01). In summary, the Padova international classification correlated with both the molecular and cellular phenotypic profiles. In practice,
p53
and
hMLH1
immunohistochemistry discriminated Ca-NIN from L-NIN and H-NIN tumors.
...
PMID:Molecular and cellular phenotypic profiles of gastric noninvasive neoplasia. 1248 Sep 14
The genomic alterations in preneoplastic lesions are summarized in this review. 3p and 9p in the lung, 9p in the bladder, 8p in the prostata, 19q and 1p in oligodendroglioma, and 22q in meningioma were reported to be deleted. Somatic mutation of
p53
was found in preneoplastic lesions of the esophagus, stomach, colon, thyroid, and astrocytoma. Adenoma-carcinoma sequence (Apc, ras,
p53
gene alterations) in colon, LKB1 gene in Peutz-Jeghers syndrome, Smad4 in juvenile polyposis, hMSH2,
hMLH1
, PMS1, PMS2 genes in HNPCC, VHL gene in kidney, WT1 in Wilms tumor, RB gene in retinoblastoma, and ret gene in MEN were reportedly altered in preneoplastic lesions involved in hereditary tumors. Cervical dysplasia and papilloma of the head and neck infected by human papilloma virus and liver infected by B-type hepatitis virus are also precancerous. Genomic instability, APC gene alteration, point mutation of K-ras in preneoplastic lesions of stomach and K-ras and p16 alterations in metaplasia of pancreas were also found. Advances in research on genomic alterations in preneoplastic lesions will contribute to prevention and early detection of cancer.
...
PMID:[Genomic alterations in preneoplastic lesions]. 1250 66
Gastric biopsy specimens were classified from category 1 (C1) to C5 according to the Vienna classification of gastrointestinal epithelial neoplasia. Fifty cases of C1, 40 cases of C2, 29 cases of C3, 19 cases of C4-1, 20 cases of C4-2+3, and 24 cases of C5 were selected and the expression of Ki-67,
p53
,
hMLH1
, and MDM2 was examined immunohistochemically to obtain useful data for the differential diagnosis of controversial cases of C2 and C4. The C2 cases, which did not show definitive neoplasia, were divided into two groups: one group had regenerative epithelium showing a relatively high degree of atypia (regenerative atypia: RA) and the other had carcinoma showing a mild degree of atypia (carcinoma of low grade atypia: CLGA). There were 0/23 RA and 12/17 CLGA cases that were positive for
p53
. Ki-67-positive cells were localized in the mitotic cell zone in RA, whereas they were irregularly distributed in CLGA. None of the cases of high-grade adenoma (C4-1) showed
p53
expression, whereas 19 out of 44 well-differentiated adenocarcinoma cases (C4-2+3 and C5) were positive for
p53
. Ki-67-positive cells were localized in the mitotic cell zone in C4-1, whereas they were irregularly distributed in C4-2+3.
hMLH1
was expressed in the proliferative cell zone of the normal foveolae, in all of the cases of adenoma (C3, C4-1) and in most cases of adenocarcinoma (C4-2,3 and C5). However, in 3 cases of C4-2+3, which showed a relatively mild degree of cellular atypia and were difficult to differentiate from high-grade adenoma (C4-1), the neoplastic cells were completely negative for
hMLH1
. MDM2 showed no characteristic expression in any gastric lesion. In conclusion,
p53
-positive cases of C2 and C4 were highly suggestive of carcinoma. Even if the case was negative for
p53
, the irregular distribution pattern of Ki-67-positive cells was highly suggestive of carcinoma.
hMLH1
-negativity in the C4 cases is strongly suggestive of carcinoma and this may be an useful marker for differentiating C4-2+3 from C4-1.
...
PMID:Differential diagnosis of atypical epithelium of biopsied gastric mucosa using immunostaining of Ki-67, p53, hMLH1 and MDM2 expression. 1263 99
To test whether a subset of esophageal squamous cell carcinomas (SCC) develop through a deficiency in DNA mismatch repair, we examined microsatellite instability (MSI) using 11 microsatellite markers including BAT-26,
hMLH1
protein expression by immunohistochemistry, and methylation status of the
hMLH1
promoter by methylation-specific polymerase chain reaction (MSP).
p53
mutations were also investigated. Microsatellite instability at one or more loci was observed in 40% (12/30) of esophageal SCC tumor samples, although only one of these tumors was categorized as high-frequency MSI (MSI-H) and none showed BAT-26 instability. While immunohistochemistry revealed decreased
hMLH1
protein expression in 27% (8/30) of the tumors,
hMLH1
promoter hypermethylation was not observed. Absence of
hMLH1
protein expression was relatively common in well-differentiated (keratinizing-type) esophageal SCC, but was not associated with
hMLH1
promoter hypermethylation.
p53
mutation was detected in 37% (11/30) and loss of heterozygosity (LOH) in 90% (27/30) of esophageal SCC samples. Our results suggested that most esophageal SCC develop through defects in tumor suppressor genes (i.e. the suppressor pathway), and that MSI in esophageal SCC probably represent random replication errors rather than being associated with DNA mismatch repair deficiency.
...
PMID:Microsatellite instability in esophageal squamous cell carcinoma is not associated with hMLH1 promoter hypermethylation. 1271 60
The mismatch repair (MMR) gene
hMLH1
is mutated in approximately 50% of hereditary non-polyposis colon cancers and transcriptionally silenced in approximately 25% of sporadic tumours of the right colon. Cells lacking
hMLH1
display microsatellite instability and resistance to killing by methylating agents. In an attempt to study the phenotypic effects of
hMLH1
downregulation in greater detail, we designed an isogenic system, in which
hMLH1
expression is regulated by doxycycline. We now report that human embryonic kidney 293T cells expressing high amounts of
hMLH1
were MMR-proficient and arrested at the G(2)/M cell cycle checkpoint following treatment with the DNA methylating agent N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), while cells not expressing
hMLH1
displayed a MMR defect and failed to arrest upon MNNG treatment. Interestingly, MMR proficiency was restored even at low
hMLH1
concentrations, while checkpoint activation required a full complement of
hMLH1
. In the MMR-proficient cells, activation of the MNNG-induced G(2)/M checkpoint was accompanied by phosphorylation of
p53
, but the cell death pathway was
p53
independent, as the latter polypeptide is functionally inactivated in these cells by SV40 large T antigen.
...
PMID:Methylation-induced G(2)/M arrest requires a full complement of the mismatch repair protein hMLH1. 1272 90
We studied the MSI (microsatellite instability) status and
p53
expression in a series of 71 gallbladder cancers (GCs) of different histologic type. All neoplasms were examined combining a microsatellite analysis at mononucleotide locus BAT-26 and an immunohistochemical study for hMSH2,
hMLH1
, and
p53
proteins and markers of gastric and intestinal differentiation. All the 71 GCs were MSS (microsatellite stable). The
p53 protein
was found in 100% of undifferentiated GCs, 67% of conventional gallbladder adenocarcinomas, 50% of mucinous adenocarcinomas, and 20% GCs with squamous differentiation. All 71 MSS tumors showed presence of immunohistochemical expression of both
hMLH1
and hMSH2 gene products. We concluded that microsatellite instability does not play a role in the developing of GC while
p53
seems to be the most important alteration found in a large proportion of these cancers, with the only exception of mucinous and squamous gallbladder carcinomas.
...
PMID:Microsatellite instability and p53 expression in gallbladder carcinomas. 1276 14
The deficiency of the DNA mismatch repair (MMR) system is involved in tumorigenesis of either familial or sporadic colorectal cancers showing microsatellite instability (MSI). To investigate the involvement of the mutated hMSH2 gene in carcinogenesis, we searched for alteration of the gene in 15 MSI tumors of Japanese patients with sporadic colorectal cancer by a polymerase chain reaction (PCR)-single strand conformation polymorphism (SSCP) and DNA sequencing analyses. We found 20 alterations including 7 novel mutations, 6 germline and one somatic. To assume an oncogenic pathway of tumor of two patients carrying germline missense mutations, G40S located in an evolutionarily conserved amino-terminal motif and Y619C in a domain interacting with either hMSH3 or hMSH6, somatic mutations in 9 target genes of the MMR defect and in the
p53
and K-ras genes and loss of heterozygosity (LOH) at the
hMLH1
and
p53
gene loci were then studied. In the tumor carrying G40S, other somatic hMSH2 mutations, G203R and 687delA in the (A)(7) repeat, and 5 one-bp deletions in the target genes were found, while no mutation in the
p53
and K-ras genes. These results indicate that G40S may affect the hMSH2 function and the tumor may be developed by a typical MSI pathway. In another tumor with Y619C, LOH at the
hMLH1
gene locus, no mutation in MMR target genes, and two-hit inactivation of the
p53
gene were detected. This MSI tumor seems to be developed by another than MSI pathway. These results indicate that there are different oncogenic pathways in the MSI sporadic colorectal cancers with germline missense mutations in the hMSH2 gene. We conclude that familial colorectal cancer-suspected cases exist in a small population of sporadic colorectal cancers.
...
PMID:Oncogenic pathway of sporadic colorectal cancer with novel germline missense mutations in the hMSH2 gene. 1279 35
Tissue microarray technology enables the analysis of hundreds of specimens by arranging numerous 0.6-mm tissue core biopsy specimens into a single paraffin block. Validation studies are necessary to evaluate the representativeness of small disks taken from the original tissue. We validated the tissue microarray technology in colorectal carcinoma by analyzing the immunohistochemical expression of proteins involved in the two main pathways of colorectal carcinogenesis:
p53 protein
for loss of heterozygosity tumors,
hMLH1
and hMSH2 proteins for microsatellite instability (MSI) tumors. We compared in 30 colorectal carcinomas (15 MSI(-) and 15 MSI(+)), 8 microarrays disks, and the whole section of the block from which they were derived. Tumoral tissue was present in 95.7% of the microarray disks. The analysis of three disks per case was comparable to the analysis of the whole section in 99.6% (
p53
), 98.8% (
hMLH1
), and 99.2% (hMSH2) of cases. In the second part we applied the tissue microarray technology to 263 consecutive cases of colorectal carcinoma, sampled by three cores. We showed that 48.5% overexpressed
p53
and 8.7% lost
hMLH1
or hMSH2. Tissue microarray technology, validated in colorectal carcinoma, appears as a useful research tool for rapid analysis of the clinical interest of molecular alterations.
...
PMID:Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression. 1280 83
Differential microsatellite instability (MSI) in tumour epithelial and stromal compartments has not been well examined for colorectal cancers. Using laser-captured microdissection, separate specimens of these compartments of 40 sporadic colorectal cancers were sampled and MSI was tested with four markers. To examine the relation between the MSI phenotype in the stroma and other genetic events and histopathological features,
p53
and K-ras gene mutations were analysed, and the expression of
p53
,
hMLH1
, and hMSH2 protein was determined by immunohistochemistry. Microsatellite instability positive results were obtained for both epithelium (34%) and stromal tissue (41%). While MSI in epithelium correlated with differentiation and Dukes' stage, that in stroma demonstrated an inverse relation, being particularly frequent in well-differentiated adenocarcinomas (54%) and Dukes' A lesions (55%). Further, a significant inverse correlation between
p53 protein
overexpression in the epithelium and MSI in the stroma was found (P=0.02475). The results suggest an alternative pathway of carcinogenesis involving stromal genetic instability in the development of colorectal cancers.
...
PMID:Possible alternative carcinogenesis pathway featuring microsatellite instability in colorectal cancer stroma. 1291 83
In this case of a dedifferentiated chondrosarcoma, we searched for genetic or epigenetic alterations in both components of the tumor, the low grade chondroblastic component, and the high grade osteosacomatouscomponent. To date, only little is known about aberrant patterns of DNA methylation in chondrosarcomas. Microdissection was used as a valuable method for clearly separating the tissues. We examined CpG island methylation of 8 tumor suppressor genes and candidate tumor suppressor genes, which are involved in different pathways: cell cycle (p21WAF1, p16INK4, p14ARF), apoptosis (DAPK, FHIT), DNA repair (
hMLH1
), and cell adherence (E-Cadherin). We found p16INK4 and E-cadherin promotor methylation in the low grade chondroid compartment of the dedifferentiated chondrosarcoma. P16INK4, FHIT, and E-cadherin were methylated in the highly malignant osteosarcomatous compartment of the tumor. Earlier investigations of this chondrosarcoma showed
p53
mutation and
p53
-LOH in the anaplastic component. As shown in this case, it was accompanied by Rb-LOH. Early methylation of p16IK4 and E-cadherin in the chondroid compartment could point to the monoclonal origin of demonstrated dedifferentiated chondrosarcoma. Further alterations, as shown in
p53
, Rb and FHIT, are responsible for the "switch" to a high grade anaplastic sarcoma.
...
PMID:Genetic and epigenetic alterations in tumor progression in a dedifferentiated chondrosarcoma. 1292 47
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>